Category Archives: SERMs

CHMP positive opinion for lasofoxifene (Fablyn), a new SERM

Press release about the positive opinion of the CHMP for Fablyn (lasofoxifene):

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE  SUMMARY OF POSITIVE OPINION for
FABLYN

International Nonproprietary Name (INN): lasofoxifene

On 18 December 2008  the Committee for Medicinal Products  for Human Use (CHMP) adopted a positive opinion, recommending to grant a marketing authorisation for the medicinal product FABLYN, 500 μg, film-coated tablets  intended for treatment of osteoporosis in postmenopausal women at increased risk of fracture. The applicant for this medicinal product is Pfizer Limited.

The active substance of FABLYN is lasofoxifene, a Selective Estrogen Receptor Modulator (ATC code not yet assigned) whose biological actions areContinue Reading

Are you a visual learner interested in learning psychopharmacology? Click here to get our videos